Susanne Erk1, Andreas Meyer-Lindenberg2, Phöbe Schmierer3, Sebastian Mohnke4, Oliver Grimm2, Maria Garbusow5, Leila Haddad2, Lydia Poehland5, Thomas W Mühleisen6, Stephanie H Witt7, Heike Tost2, Peter Kirsch8, Nina Romanczuk-Seiferth5, Björn H Schott4, Sven Cichon9, Markus M Nöthen10, Marcella Rietschel7, Andreas Heinz5, Henrik Walter11. 1. Department of Psychiatry, Charité Universitätsmedizin Berlin, Campus Mitte; Division of Mind and Brain Research, Charité Universitätsmedizin Berlin, Campus Mitte. Electronic address: susanne.erk@charite.de. 2. Department of Psychiatry, Central Institute of Mental Health, University of Heidelberg, Mannheim. 3. Department of Psychiatry, Charité Universitätsmedizin Berlin, Campus Mitte; Division of Mind and Brain Research, Charité Universitätsmedizin Berlin, Campus Mitte; Berlin School of Mind and Brain, Humboldt University of Berlin, Berlin. 4. Department of Psychiatry, Charité Universitätsmedizin Berlin, Campus Mitte; Division of Mind and Brain Research, Charité Universitätsmedizin Berlin, Campus Mitte. 5. Department of Psychiatry, Charité Universitätsmedizin Berlin, Campus Mitte. 6. Department of Genomics, Life & Brain Center, University of Bonn, Bonn; Institute of Human Genetics, University of Bonn, Bonn; Institute of Neuroscience and Medicine (INM-1), Research Centre Jülich, Jülich, Germany. 7. Department of Genetic Epidemiology, Central Institute of Mental Health, University of Heidelberg, Mannheim. 8. Department of Psychology, Central Institute of Mental Health, University of Heidelberg, Mannheim. 9. Department of Biomedicine, University of Basel, Basel, Switzerland. 10. Department of Genomics, Life & Brain Center, University of Bonn, Bonn; Institute of Human Genetics, University of Bonn, Bonn. 11. Department of Psychiatry, Charité Universitätsmedizin Berlin, Campus Mitte; Division of Mind and Brain Research, Charité Universitätsmedizin Berlin, Campus Mitte; Berlin School of Mind and Brain, Humboldt University of Berlin, Berlin; Department of Psychiatry, University of Bonn, Bonn.
Abstract
BACKGROUND: Variation in CACNA1C has consistently been associated with psychiatric disease in genome-wide association studies. We have previously shown that healthy carriers of the CACNA1C rs1006737 risk variant exhibit hippocampal and perigenual anterior cingulate (pgACC) dysfunction during episodic memory recall. To test whether this brain systems-level abnormality is a potential intermediate phenotype for psychiatric disorder, we studied unaffected relatives of patients with bipolar disorder, major depression, and schizophrenia. METHODS: The study population comprised 188 healthy first-degree relatives of patients with bipolar disorder (n=59), major depression (n=73), and schizophrenia (n=56) and 110 comparison subjects from our discovery study who were genotyped for rs1006737 and underwent functional magnetic resonance imaging while performing an episodic memory task and psychological testing. Group comparisons were analyzed using SPM8 and PASW Statistics 20. RESULTS: Similar to risk allele carriers in the discovery sample, relatives of index patients exhibited hippocampal and pgACC dysfunction as well as increased scores in depression and anxiety measures, correlating negatively with hippocampal activation. Carrying the rs1006737 risk variant resulted in a stronger decrease of hippocampal and pgACC activation in relatives, indicating an additive effect of CACNA1C variation on familial risk. CONCLUSIONS: Our findings implicate abnormal perigenual and hippocampal activation as a promising intermediate phenotype for psychiatric disease and suggest a pathophysiologic mechanism conferred by a CACNA1C variant being implicated in risk for symptom dimensions shared among bipolar disorder, major depression, and schizophrenia.
BACKGROUND: Variation in CACNA1C has consistently been associated with psychiatric disease in genome-wide association studies. We have previously shown that healthy carriers of the CACNA1Crs1006737 risk variant exhibit hippocampal and perigenual anterior cingulate (pgACC) dysfunction during episodic memory recall. To test whether this brain systems-level abnormality is a potential intermediate phenotype for psychiatric disorder, we studied unaffected relatives of patients with bipolar disorder, major depression, and schizophrenia. METHODS: The study population comprised 188 healthy first-degree relatives of patients with bipolar disorder (n=59), major depression (n=73), and schizophrenia (n=56) and 110 comparison subjects from our discovery study who were genotyped for rs1006737 and underwent functional magnetic resonance imaging while performing an episodic memory task and psychological testing. Group comparisons were analyzed using SPM8 and PASW Statistics 20. RESULTS: Similar to risk allele carriers in the discovery sample, relatives of index patients exhibited hippocampal and pgACC dysfunction as well as increased scores in depression and anxiety measures, correlating negatively with hippocampal activation. Carrying the rs1006737 risk variant resulted in a stronger decrease of hippocampal and pgACC activation in relatives, indicating an additive effect of CACNA1C variation on familial risk. CONCLUSIONS: Our findings implicate abnormal perigenual and hippocampal activation as a promising intermediate phenotype for psychiatric disease and suggest a pathophysiologic mechanism conferred by a CACNA1C variant being implicated in risk for symptom dimensions shared among bipolar disorder, major depression, and schizophrenia.
Authors: Hengyi Cao; Sarah C McEwen; Yoonho Chung; Oliver Y Chén; Carrie E Bearden; Jean Addington; Bradley Goodyear; Kristin S Cadenhead; Heline Mirzakhanian; Barbara A Cornblatt; Ricardo E Carrión; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Aysenil Belger; Larry J Seidman; Heidi Thermenos; Ming T Tsuang; Theo G M van Erp; Elaine F Walker; Stephan Hamann; Alan Anticevic; Scott W Woods; Tyrone D Cannon Journal: Schizophr Bull Date: 2019-06-18 Impact factor: 9.306
Authors: Tyler M Moore; Monica E Calkins; Theodore D Satterthwaite; David R Roalf; Adon F G Rosen; Ruben C Gur; Raquel E Gur Journal: J Psychiatr Res Date: 2019-06-01 Impact factor: 4.791
Authors: Cameron S Carter; Carrie E Bearden; Edward T Bullmore; Daniel H Geschwind; David C Glahn; Raquel E Gur; Andreas Meyer-Lindenberg; Daniel R Weinberger Journal: Biol Psychiatry Date: 2016-08-20 Impact factor: 13.382
Authors: Stefanie Uhrig; David Vandael; Andrea Marcantoni; Nina Dedic; Ainhoa Bilbao; Miriam A Vogt; Natalie Hirth; Laura Broccoli; Rick E Bernardi; Kai Schönig; Peter Gass; Dusan Bartsch; Rainer Spanagel; Jan M Deussing; Wolfgang H Sommer; Emilio Carbone; Anita C Hansson Journal: Neuropsychopharmacology Date: 2016-12-01 Impact factor: 7.853
Authors: Carolin Wackerhagen; Torsten Wüstenberg; Sebastian Mohnke; Susanne Erk; Ilya M Veer; Johann D Kruschwitz; Maria Garbusow; Lydia Romund; Kristina Otto; Janina I Schweiger; Heike Tost; Andreas Heinz; Andreas Meyer-Lindenberg; Henrik Walter; Nina Romanczuk-Seiferth Journal: Neuropsychopharmacology Date: 2017-03-15 Impact factor: 7.853
Authors: Chenyang Tao; Thomas E Nichols; Xue Hua; Christopher R K Ching; Edmund T Rolls; Paul M Thompson; Jianfeng Feng Journal: Neuroimage Date: 2016-09-22 Impact factor: 6.556